Clinical trial · Observational
Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer
Predictive Role of Circulating Biomarkers Involved in Angiogenesis in Metastatic Kidney Cancer in the Era of New Therapeutic Associations: Immunotherapies, Anti-angiogenic
NCT05285579CI-TRIAL-00065799ANGIOCORunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, exploratory, prospective study to identify angiogenesis and immune-related biomarkers predictive of progression free survival in patients with metastatic or advanced renal cell carcinoma treated by a combination of immunotherapy and antiangiogenic.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cancer | — | UNRESOLVED | — |
| Renal Cancer Metastatic | — | UNRESOLVED | — |
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood collection | Biological | — | UNRESOLVED |
| Tumour samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- TKI+ICI
- description
- Therapeutic combination tyrosine kinase inhibitor (TKI) + immune checkpoint inhibitors (ICI)
- interventionNames
- Biological: Blood collection
- Other: Tumour samples
- label
- ICI+ICI
- description
- Therapeutic combination with different immune checkpoint inhibitors (ICI)
- interventionNames
- Biological: Blood collection
- Other: Tumour samples
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 24 months
- description
- Time from inclusion to progression documented by imaging and based on RECIST 1.1 and iRECIST criteria or patient death. The iRECIST criteria use the same methods of monitoring tumor lesions as the RECIST 1.1 criteria but a confirmation 4-6 weeks after suspicion of progression is required to confirm or rule out progression because patients undergoing immunotherapy may present pseudo-progressions.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven advanced or metastatic renal carcinoma * treated in first line with an ICI-ICI or ITK-ICI combination (following current recommendations at inclusion) Exclusion Criteria: * Previous systemic treatment for renal cell carcinoma * Other cancer developed in the last 5 years except local forms apparently healed as basal cell cancer. * Contraindication for ICI-ICI or TKI-ICI combinations recommended on 1st line * Refusal to participate in the study * No affiliation to a social security regime (beneficiary or entitled) * Vulnerable patients as defined by french law (Public Heath Code sections L1121 -5 to L1121-8) : * Major patient subjected to legal protection (guardianship, curatorship, protection of justice) * Pregnant or breastfeeding woman
References
Publications (0)
Data not yet available
No reference posted for this study.